Immunogenic cell death modalities and their impact on cancer treatment.
about
Oncolytic viruses as therapeutic cancer vaccinesAn Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant GliomaCell death in the maintenance and abrogation of tolerance: the five Ws of dying cellsModulation of inflammation by autophagy: Consequences for human diseaseTumor cell lysates as immunogenic sources for cancer vaccine designPrimary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumorsHigh-mobility group box 1 and cancer.Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer.Calreticulin: non-endoplasmic reticulum functions in physiology and disease.Transgenic expression of Hsc70 in pancreatic islets enhances autoimmune diabetes in response to beta cell damageRIG-I enhanced interferon independent apoptosis upon Junin virus infection.Smoking exposure induces human lung endothelial cell adaptation to apoptotic stress.What's the place of immunotherapy in malignant mesothelioma treatments?Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.Complement-dependent modulation of antitumor immunity following radiation therapy.Genetic control of necrosis - another type of programmed cell death.TRAIL-expressing CD8+ T cells mediate tolerance following soluble peptide-induced peripheral T cell deletion.Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects.The progression of cell death affects the rejection of allogeneic tumors in immune-competent mice - implications for cancer therapy.Upregulation of heat shock proteins and the promotion of damage-associated molecular pattern signals in a colorectal cancer model by modulated electrohyperthermia.Stimulation of anti-tumor immunity by photodynamic therapyDendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccinationElimination of metastatic melanoma using gold nanoshell-enabled photothermal therapy and adoptive T cell transferThe emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma CellsDown-regulation of HMGB1 expression by shRNA constructs inhibits the bioactivity of urothelial carcinoma cell lines via the NF-κB pathwayImmune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistanceCan dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells?Antagonism between curcumin and the topoisomerase II inhibitor etoposide: a study of DNA damage, cell cycle regulation and death pathways.Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy.The vitamin E analogue α-TEA stimulates tumor autophagy and enhances antigen cross-presentationSustained tumour eradication after induced caspase-3 activation and synchronous tumour apoptosis requires an intact host immune responseT-cell immunoglobulin and mucin domain 1 deficiency eliminates airway hyperreactivity triggered by the recognition of airway cell death.Use of anti-cancer drugs, mitocans, to enhance the immune responses against tumors.Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.Activation-induced CD154 expression abrogates tolerance induced by apoptotic cellsiNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells.Doxorubicin treatment induces tumor cell death followed by immunomodulation in a murine neuroblastoma model.
P2860
Q21245758-80DE0F8D-613B-4A2F-BD4E-C7442040D5DDQ26770399-7751B976-CBFD-4DA0-B38A-90DD328C512CQ26999223-A4A7CCC7-8ACC-4AE3-966E-613C15D3242DQ28082840-4C5521E3-9F01-41F3-B843-0F4EC2937C17Q28083469-D4DEDFC8-7E61-4C68-B78D-BE9F685291ADQ28481417-40D21D08-43F4-469A-9612-42EE8BF6277AQ30408302-3A5C8F0E-69C1-4C5B-A17E-AFF240B1AF20Q33638306-91045C88-11A2-47EE-82C8-440C3016EC5EQ33693936-E4F76A2A-7678-4EB3-A977-04B4E942C9D0Q33694634-2E3C70BA-00A3-4AEB-A13A-BE9BEEEC1831Q33737841-4E6507CB-30D5-4BC8-83C8-FEAA5FEBBF8DQ33740309-A8B41D9E-6B92-40FC-9CDC-5919F0B08D34Q33756670-5F9F5AF9-0DC2-45DC-9FB1-E6FADDF54186Q33781142-6D920694-7EA8-4BE5-869F-01B695086807Q33828114-CF5FF244-31D8-45E3-A83A-86B54F41600DQ34063811-DB3FE560-E7A7-45E4-AAA9-EF78310AF030Q34361274-8A92744E-AC2C-4BD2-A227-882230446C7DQ34378771-0CCC0183-F126-42CF-AD00-D5F6366E0616Q34429312-0BE091E3-391D-4C45-813C-665256CE33B1Q34488368-214A47FA-50C4-47BF-8F91-6FAE7F9C72D4Q34628990-3751CE67-1428-4AEC-9911-ED8656CD36D8Q34697795-09EF690C-CAD2-4FBF-BF73-24619C4A7A6AQ34759603-5A4EB5D0-1C47-4A0B-AC23-64555EF82546Q34919077-BC14C257-A169-4654-9F1F-742E1BC70E2CQ35058213-E2EC9104-B502-4983-B3FE-C948E6F5D544Q35527165-3EBB7F51-C302-4F01-9104-B1B585A4B82BQ35636540-2C7AFBD8-6949-42E0-AC1C-1293445ADEC4Q35913266-D8720541-6F57-4C6A-9455-AC979F97AAE1Q36125878-48E030BF-FEAC-4B36-A2B9-34B05F558E48Q36255729-72A9EB47-29CB-40FC-B3EF-6FF9CF2BCF3CQ36289907-CD8F28E1-F6E2-4CE4-9641-895E337FC35EQ36391595-107F6214-A199-41BD-A16D-9FAF6DFE8CC4Q36620591-259F5EDA-63F3-4DB9-B738-CC6F1958DA0BQ36747309-AA249FF1-4E4A-4195-842A-EF8195E54F39Q37067433-B267CE3B-5D32-4155-B35E-0F2108D4AA77Q37308070-942EACBC-F279-4CB6-AABD-A9BAAFBD4C0FQ37403279-3EC0D80D-FA29-4256-A902-13894FB4391CQ37440899-8B66A0B9-46C4-410C-B339-A3095AAFFAA7Q37448441-948B90DE-10FC-4DEB-963D-7F91306817DEQ37574979-708C37FB-2AFB-41CE-97D4-76AF51E79106
P2860
Immunogenic cell death modalities and their impact on cancer treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunogenic cell death modalities and their impact on cancer treatment.
@en
Immunogenic cell death modalities and their impact on cancer treatment.
@nl
type
label
Immunogenic cell death modalities and their impact on cancer treatment.
@en
Immunogenic cell death modalities and their impact on cancer treatment.
@nl
prefLabel
Immunogenic cell death modalities and their impact on cancer treatment.
@en
Immunogenic cell death modalities and their impact on cancer treatment.
@nl
P50
P1433
P1476
Immunogenic cell death modalities and their impact on cancer treatment.
@en
P2093
Frederic Schlemmer
P2888
P304
P356
10.1007/S10495-008-0303-9
P577
2009-04-01T00:00:00Z